Navigation Links
Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy

study sites, have also had reported tumor shrinkage. All patients, however, showed disease progression at or after week 8. The maximum tolerated dose was 20 mCi/m(2) with bone marrow being the dose-limiting organ.

"Because of the refractory nature of pancreatic cancer, single agent treatment is not expected to offer clinical benefit. Based on this Phase I experience, combined/sequential treatment with chemotherapy and fractionated radioimmunotherapy is being considered for future trials," commented Dr. Gulec.

"We have presented these preliminary results to the FDA and are in discussion with the regulatory authority for a new Phase I dose-escalation study for 90Y-hPAM4 in combination with gemcitabine using smaller Y-90 doses repeatedly," added Cynthia L. Sullivan, President and CEO of Immunomedics.

In addition, the Company presented two posters at today's meeting on the pretargeting of pancreatic cancer and B-cell lymphoma using new bispecific antibodies constructed from the Company's proprietary platform technology for protein engineering termed the dock-and-lock (DNL).

One poster was on TF10, which is a DNL construct with two binding sites for the same MUC1 antigen targeted by PAM4, and a single binding site for the histamine-succinyl-glycine (HSG) peptide. Initial therapy studies showed that pretargeting with TF10 and Y-90 labeled HSG peptide can effectively cause the complete regression of human pancreatic cancer in mice at doses well below the maximum tolerated level.

The other poster was on TF4 for the pretargeting of B-cell lymphoma. Constructed with two sites that target the CD20 antigen and one for the HSG peptide, TF4, when used in combination with radiolabeled HSG-peptide, is highly effective for imaging lymphoma implanted in mouse models either subcutaneously or intravenously. Early results indicate therapy of tumors can be achieved with 500 microCi of Y-90 or less.

About hPAM4

hPAM4 is a humanized monoclo
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:9/30/2014)... 2014 The report based on ... Share, Growth and Forecast, 2007 - 2017," elaborated by ... 20.8 billion in 2012 and is further expected to ... CAGR of 7.3% from 2012 to 2017. ... purposes, especially to prevent chronic diseases that may occur ...
(Date:9/30/2014)... , September 30, 2014 ... the CSF (Cerebrospinal Fluid) backflow of the Eldor spinal ... of the single hole pencil point spinal needles of ... Braun. Spinal anesthesia is an excellent type ... Orthopedics, Urology, General Anesthesia, etc. It is ...
(Date:9/30/2014)...   Acutus Medical, Inc. (ACM), a ... Cardiac Chamber Imaging and Dipole Density Mapping system to ... complex cardiac arrhythmias, including atrial fibrillation, announced it has ... imaging/mapping system as well as bring to market a ... to complete work on the AcQMap TM High ...
Breaking Medicine Technology:Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... When it comes to breast cancer, a physician,s ability ... of treatment depends on the quality of information revealed through ... the most advanced technology in breast cancer detection with positron ... PEM scanners in the Chicagoland area. Essentially, PEM ...
... BETHLEHEM, Pa., Nov. 1, 2011 Saladax Biomedical, Inc., ... assays to achieve the promise of personalized medicine for ... M.D., has accepted to chair the company,s scientific advisory ... as chief of the Division of Hematology/Oncology in the ...
Cached Medicine Technology:Palos Offers New Technology in the Fight Against Breast Cancer 2Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Company's Scientific Advisory Board 2Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Company's Scientific Advisory Board 3
(Date:9/30/2014)... Ohio (PRWEB) September 30, 2014 Life ... which provides CHL access to Life Length’s proprietary Telomere ... advanced and comprehensive telomere test on the market today, ... reports the percentage of short telomeres, providing the most ... Vice Chairman of the Department of Cell Biology at ...
(Date:9/30/2014)... Market Research Report on Global and ... in-depth market survey on Global and Chinese Cialis ... of Cialis including its classification, application and manufacturing ... top manufacturers of Cialis listing their product specification, ... The report further analyzes quantitatively 2009-2014 global and ...
(Date:9/30/2014)... 30, 2014 Catalent Pharma Solutions ... delivery technologies and development solutions for drugs, biologics ... agenda for the 25th Annual CPhI Worldwide Exhibition ... 6th to 9th. , Catalent is showcasing a ... during the show, including its facilities in China ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ADOAMNI, ... first “crowdfunding” campaign through GoFundMe. The campaign, which surpassed ... for a portion of the funds necessary to convert ... for the Stockton Unified School District (SUSD). The campaign ... provide a portion of the funds necessary for the ...
(Date:9/30/2014)... The American Parkinson Disease ... supporting seven Research grants to junior investigators pursuing ... support post-doctoral scientists whose research training holds promise ... and treatment of Parkinson’s disease, and eight Centers ... medical centers across the country intended to strengthen ...
Breaking Medicine News(10 mins):Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 3Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 2Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 3Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 4
... reason for hope, experts say , , FRIDAY, Sept. 28 ... to treat the autoimmune disease lupus is building up ... an upbeat tone, researchers from across the United States ... Research Institute (LRI) of the improving outlook for patients ...
... The Branded Pharmaceutical,Association (BPA) represents specialty manufacturers, ... of the BPA produce,market or distribute Legacy ... drugs, with a history of safety and ... these products are manufactured in FDA licensed ...
... YORK, Sept. 28 According to the ... nearly one million Latinos received,physician-administered aesthetic procedures ... Flor Mayoral, a board certified,dermatologist in Miami, ... it is important that women make informed ...
... Senior Living,Inc. (NYSE: SRZ ) today announced ... being conducted by the Special Independent Committee of ... Sarbanes-Oxley,Section 404 internal control review efforts and provided ... Investigation As previously disclosed, in December 2006, ...
... Calif., Sept. 28 TJ Enterprises, LLC,announced ... a safe,alternative in the treatment of baby ... This comes after the U.S. Food and ... unopened,retail samples of a non-homeopathic gripe water, ...
... Care,Management Association (PCMA) released the following statement today,supporting ... the,House Energy and Commerce Subcommittee on Health: ... earlier,this week that would fix the flawed Average ... Reduction Act. "PCMA supports the decision to ...
Cached Medicine News:Health News:Better Lupus Treatments on the Horizon 2Health News:Better Lupus Treatments on the Horizon 3Health News:Better Lupus Treatments on the Horizon 4Health News:The Branded Pharmaceutical Association Comments on Hydrocodone 2Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 2Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 3Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 4Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 5Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 6Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 7Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 8Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 9Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 10Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 11Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 12Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 13Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 14Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 15Health News:After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative 2
The VPAP III ST is a complete system solution for SDB, providing comfortable and effective bilevel treatment with additional treatment modes. The VPAP III ST is an effective business solution for cli...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
... The BiPAP Pro with Bi-Flex bi-level ... time that the BiPAP Pro takes to ... includes Digital Auto-Trak Sensitivity™ which automatically triggers ... expiratory pressures based on the patients breathing ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
Medicine Products: